What is the recommended dosage and administration of ertapenem (a carbapenem antibiotic) injection for the treatment of complicated bacterial infections in patients with impaired renal function?

Ertapenem Dosing and Administration for Complicated Bacterial Infections

Standard Dosing in Adults with Normal Renal Function

For adults 13 years and older with normal renal function (creatinine clearance >90 mL/min/1.73 m²), ertapenem is administered as 1 gram intravenously once daily, infused over 30 minutes. 1

• The once-daily dosing regimen is a key advantage of ertapenem compared to other carbapenems that require multiple daily doses 2, 3
• Ertapenem can be administered intravenously for up to 14 days or intramuscularly for up to 7 days 1
• Do not mix or co-infuse ertapenem with other medications, and do not use diluents containing dextrose 1

Dosing by Infection Type (Normal Renal Function)

Complicated Intra-Abdominal Infections

• 1 gram IV once daily for 5-14 days 1
• Ertapenem is recommended as an appropriate option for non-critically ill patients at risk for ESBL-producing Enterobacteriaceae 4
• Clinical cure rates of 84-85% have been demonstrated, equivalent to piperacillin-tazobactam 2, 5

Complicated Urinary Tract Infections (Including Pyelonephritis)

• 1 gram IV once daily for 10-14 days 1
• Duration includes possible switch to oral therapy after at least 3 days of parenteral therapy once clinical improvement is demonstrated 1
• Microbiological cure rates of 90.5% have been achieved for infections caused by Enterobacteriaceae 5
• Ertapenem is specifically recommended for ESBL-producing E. coli UTIs 6

Community-Acquired Pneumonia

• 1 gram IV once daily for 10-14 days 1
• Duration includes possible switch to oral therapy after at least 3 days of parenteral therapy once clinical improvement is demonstrated 1
• Clinical cure rates of 92-95% have been demonstrated 2, 5
• Ertapenem is effective for CAP caused by typical respiratory pathogens including Enterobacteriaceae 7, 2

Complicated Skin and Skin Structure Infections

• 1 gram IV once daily for 7-14 days 1
• Adult patients with diabetic foot infections may receive up to 28 days of treatment (parenteral or parenteral plus oral switch therapy) 1
• Ertapenem has not been studied in diabetic foot infections with concomitant osteomyelitis 1
• Clinical cure rates of 81-82% have been achieved 2, 5

Acute Pelvic Infections

• 1 gram IV once daily for 3-10 days 1
• Indications include postpartum endomyometritis, septic abortion, and post-surgical gynecologic infections 1
• Clinical cure rates of 86.8-94% have been demonstrated 2, 5

Critical Dosing Adjustments for Renal Impairment

Creatinine Clearance >30 mL/min/1.73 m²

• No dosage adjustment necessary 1

Severe Renal Impairment (CrCl ≤30 mL/min/1.73 m²)

• Reduce dose to 500 mg IV once daily 1
• This applies to both severe renal impairment and end-stage renal disease (CrCl ≤10 mL/min/1.73 m²) 1

Patients on Hemodialysis

• Administer 500 mg daily as the standard dose 1
• If ertapenem is given within 6 hours prior to hemodialysis, give a supplementary dose of 150 mg after the dialysis session 1
• If ertapenem is given at least 6 hours prior to hemodialysis, no supplementary dose is needed 1
• There are no data for patients undergoing peritoneal dialysis or hemofiltration 1

Pediatric Dosing (3 Months to 12 Years)

For pediatric patients 3 months to 12 years of age, administer 15 mg/kg IV twice daily, not to exceed 1 gram per day. 1

• The same infection-specific treatment durations apply as for adults 1
• Ertapenem is included in guidelines for pediatric complicated intra-abdominal infections as an acceptable broad-spectrum regimen 8
• There are no data in pediatric patients with renal impairment or on hemodialysis 1

Hepatic Impairment

No dose adjustment recommendations can be made for patients with hepatic impairment due to lack of data. 1

• Dosing modifications have not been recommended for adults based on gender, age, weight, or liver disease in the absence of renal impairment 3

Clinical Spectrum and Appropriate Use

Antimicrobial Coverage

• Ertapenem has broad-spectrum activity against Gram-negative bacteria (including Enterobacteriaceae) and Gram-positive aerobic and anaerobic bacteria 2, 9
• Ertapenem retains activity against most strains with AmpC and extended-spectrum beta-lactamases (ESBLs) 9, 10
• Clinical response rates of 92% have been achieved for ESBL-producing Gram-negative bacterial infections, with 94% survival to hospital discharge 10

Important Spectrum Limitations

• Ertapenem is less active against non-fermenters (such as Pseudomonas aeruginosa and Acinetobacter baumannii) compared to imipenem and meropenem 9
• Ertapenem lacks activity against MRSA and should not be used for suspected methicillin-resistant staphylococcal infections 8

Pharmacokinetic Considerations

• Ertapenem has a plasma half-life of approximately 4 hours in healthy volunteers 9
• Following a 1 gram IV infusion, the maximum plasma concentration (Cmax) is 155 mg/L for total drug and 13 mg/L for free drug 9
• Excretion is largely renal, divided equally between native drug and an open-ring derivative 9
• Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes, so significant drug interactions are not expected 3

Preparation and Administration

Intravenous Administration

• Reconstitute 1 gram vial with 10 mL of Water for Injection, 0.9% Sodium Chloride Injection, or Bacteriostatic Water for Injection 1
• Shake well to dissolve and immediately transfer contents to 50 mL of 0.9% Sodium Chloride Injection 1
• Complete the infusion within 6 hours of reconstitution 1
• Infuse over 30 minutes 1

Intramuscular Administration (Alternative Route)

• Reconstitute 1 gram vial with 3.2 mL of 1.0% lidocaine HCl injection (without epinephrine) 1
• Administer by deep intramuscular injection into a large muscle mass (gluteal muscles or lateral thigh) 1
• Use the reconstituted IM solution within 1 hour after preparation 1
• The reconstituted IM solution should not be administered intravenously 1

Common Pitfalls and Caveats

Avoid Inappropriate Use

• Do not use ertapenem for infections likely caused by Pseudomonas aeruginosa or Acinetobacter species, as these non-fermenters are outside ertapenem's spectrum 9
• For critically ill patients with healthcare-associated intra-abdominal infections at high risk for multidrug-resistant organisms, broader-spectrum carbapenems (meropenem, imipenem, doripenem) are preferred over ertapenem 4

Carbapenem Stewardship

• Ertapenem is preferred over meropenem/imipenem for ESBL infections due to once-daily dosing and reserving broader carbapenems for more resistant organisms 6
• Ertapenem has particular value in treating polymicrobial infections where Enterobacteriaceae and anaerobic bacteria are involved 2
• Consider carbapenem-sparing alternatives when susceptibility data allow for narrower-spectrum therapy 4

Monitoring Requirements

• Clinical response should be evident within 48-72 hours of initiating therapy 6
• If no improvement occurs by 72 hours, obtain repeat cultures to assess for treatment failure or resistant organisms 6
• Culture and susceptibility results should guide continuation or modification of therapy 1